--- title: 'Morning Brief — Wednesday, November 4, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-11-04' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-11-04' audio: 'https://media.doc.social/podcasts/morning-brief/2026-11-04.mp3' --- # Morning Brief — Wednesday, November 4, 2026 Bioventus Q3 2026: revenue $142.4M (+2.7%); Pain Treatments +6.2% on Durolane, PRP and PNS; Surgical Solutions +0.7% (U.S. -2.8%) on softer bone graft substitutes; Restorative Therapies -3.4% on EXOGEN; FY26 net sales guidance cut to $590-595M from $600-610M; adjusted EPS $0.75-0.79 reaffirmed; strategic alternatives review (opened Aug 5 after an unsolicited proposal) continues · Highridge… ## Summary 4 stories this morning, for surgeons and the people who support them. - **Bioventus Q3 2026: revenue $142.4M (+2.7%); Pain Treatments +6.2% on Durolane, PRP and PNS; Surgical Solutions +0.7% (U.S. -2.8%) on softer bone graft substitutes; Restorative Therapies -3.4% on EXOGEN; FY26 net sales guidance cut to $590-595M from $600-610M; adjusted EPS $0.75-0.79 reaffirmed; strategic alternatives review (opened Aug 5 after an unsolicited proposal) continues** — Bioventus reported Q3 results on November 2 and lowered full-year sales guidance to $590-595M (4-5% growth) from $600-610M (6-7%), while its board's review of strategic alternatives, including a possible sale, continues with no timetable. [Source](https://www.sec.gov/Archives/edgar/data/1665988/000166598826000050/bioventusex-991q32026.htm) - **Highridge Medical, the former ZimVie spine business owned by H.I.G. Capital, names Rob Fredericks CEO (ex-Lighteum Medical, Merit Medical, C.R. Bard; spine experience at Medtronic); Eric Major remains executive chairman** — On November 2 Highridge named Rob Fredericks chief executive, filling the post Rebecca Whitney said in June she was leaving; Highridge carries Mobi-C, the activL lumbar disc (limited launch Feb 2026) and The Tether (UnitedHealthcare coverage April 2026). [Source](https://highridgemedical.com/wp-content/uploads/CEO-Press-Release-Highridge-Medical-Names-Rob-Fredericks-Chief-Executive-Officer.pdf) - **Bone Joint J, Norwegian Arthroplasty and Hip Fracture Registers: in 204,041 primary hip arthroplasties (2005-2025), reoperation for periprosthetic femoral fracture in men was ~9x higher with polished taper-slip and uncemented collarless stems and ~4x with uncemented collared stems vs cemented composite-beam stems; age thresholds for excess risk differed by sex and design** — Registry analysis concluding composite-beam stems should be preferred at least in men over 75 and women over 70, with collared stems the best uncemented option and taper-slip stems high-risk in men at all ages. [Source](https://pubmed.ncbi.nlm.nih.gov/42966374/) - **J Arthroplasty double-blind RCT, 86 primary TKA patients: extended oral tranexamic acid (1.95 g/day POD 1-3) after standard IV TXA did not improve VAS pain at any point to 12 weeks, ROM, opioid use or ambulation vs placebo** — Connecticut Joint Replacement Institute trial found no benefit from extended oral TXA after primary TKA; authors say broad use of the protocol may not be warranted. [Source](https://pubmed.ncbi.nlm.nih.gov/42971442/) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._